Percutaneous Coronary Intervention (PCI)
Also known as: PCI- Percutaneous Coronary Intervention / Percutaneous Coronary Interventions / PCI / Percutaneous Coronary Intervention / PCI - Percutaneous coronary intervention / Percutaneous coronary intervention (procedure)
Drug | Drug Name | Drug Description |
---|---|---|
DB00054 | Abciximab | A monoclonal anti-glycoprotein IIb/IIIa receptor antibody used to prevent thrombosis during percutaneous coronary intervention. |
DB00945 | Acetylsalicylic acid | A salicylate used to treat pain, fever, inflammation, migraines, and reducing the risk of major adverse cardiovascular events. |
DB00278 | Argatroban | A synthetic direct thrombin inhibitor used for the prevention and treatment of thrombosis related to heparin use. |
DB00006 | Bivalirudin | A direct thrombin inhibitor used to treat heparin-induced thrombocytopenia and to prevent thrombosis during percutaneous coronary intervention. |
DB06441 | Cangrelor | A P2Y12 platelet receptor antagonist used during percutaneous coronary intervention to reduce the risk for periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST). |
DB01225 | Enoxaparin | A low molecular weight heparin used for the prophylaxis of deep vein thrombosis and ischemic complications of unstable angina and non-Q-wave myocardial infarction. |
DB00063 | Eptifibatide | A peptide-based antagonist for glycoprotein IIb/IIIa used in the medical management of myocardial infarction and as an adjunct to percutaneous coronary intervention. |
DB01109 | Heparin | An anticoagulant indicated for thromboprophylaxis and to treat thrombosis associated with a variety of conditions such as pulmonary embolism and atrial fibrillation. |